- Home
- AGMB vs HBCP Comparison
AGMB vs HBCP Comparison
Compare AGMB & HBCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGMB | HBCP |
|---|---|---|
| Founded | 2017 | 1908 |
| Country | Belgium | United States |
| Employees | 62 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.4M | 453.4M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | AGMB | HBCP |
|---|---|---|
| Price | $11.45 | $64.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $32.00 | ★ $65.50 |
| AVG Volume (30 Days) | ★ 64.9K | 61.6K |
| Earning Date | 04-23-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 1.98% |
| EPS Growth | N/A | ★ 29.01 |
| EPS | N/A | ★ 1.45 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.86 | $3.97 |
| P/E Ratio | ★ N/A | $44.79 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.00 | $48.30 |
| 52 Week High | $17.45 | $65.95 |
Technical Indicators
Market Signals| Indicator | AGMB | HBCP |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 58.75 |
| Support Level | $9.62 | $61.84 |
| Resistance Level | $12.29 | $65.86 |
| Average True Range (ATR) | 0.93 | 1.38 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 36.97 | 76.36 |
Price Performance
Historical ComparisonAbout AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
About HBCP Home Bancorp Inc.
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities.It is holding company for Home Bank, N.A. The principal sources of funds are customer deposits, repayments of loans, repayments of investments, and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.